-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] For the pharmaceutical industry, innovation-driven transformation will be an important task during the "14th Five-Year Plan" period
.
China needs to continuously improve its original innovation capabilities, speed up innovation and upgrade, improve innovation incentive policies, and promote the application of innovative products
.
The "14th Five-Year Plan" period will be a critical period for China's pharmaceutical innovation-driven transformation
.
According to the industry, with the investment of a large number of innovative resources in the past ten years, a large number of new drugs under research in China have entered the harvest period
.
It is predicted that during the "14th Five-Year Plan" period, there may be more than 200 domestic new drug applications (NDA)/biological product license applications (BLA), and more than 100 new drugs may be approved, shifting from the R&D investment stage to the commercialization stage
.
How to innovate in the pharmaceutical industry? Insiders pointed out that basic research is the source of medical innovation
.
In recent years, the total R&D investment in China's pharmaceutical field has increased significantly, and the level of basic pharmaceutical research has made great progress, "but there is still a big gap with the world's advanced level, mainly due to the unreasonable distribution of R&D investment, the need to improve high-quality cutting-edge research, and the transformation of patents into production.
Problems such as troubles, lack of professional institutions and talents
.
" the person said
.
It suggested that in terms of pharmaceutical innovation, China needs to make efforts from three aspects: optimizing the talent training and evaluation system, exploring the upgrading of the main innovation model, and optimizing the way of public investment in basic research, and continue to promote basic research in pharmaceutical innovation
.
Establish a talent evaluation system that pursues original innovation and encourages the transformation of basic research results, strengthens the cultivation of compound research and industrial talents with backgrounds in science, medicine, pharmacy, information technology, etc.
, to build a talent exchange channel between academia, medicine, and industry, and promote a reasonable two-way circulation of talents to fully connect basic research, clinical needs and commercial applications
.
In addition, some people also suggested to increase funding for basic research on drug innovation and optimize the environment for drug research and development
.
For example, the establishment of scientific research funds suitable for the joint application of pharmaceutical companies and scientific research institutions such as universities, the introduction of more tax incentives and other policies to expand socialized non-profit institutions to increase funding for drug research and development,
etc.
It is understood that for pharmaceutical innovation, the "14th Five-Year Plan for the Development of Pharmaceutical Industry" (referred to as the "Plan") proposes the direction and focus of pharmaceutical innovation in the next step
.
Among them, the "Plan" pointed out that the original innovation ability should be improved and the innovation and upgrading should be accelerated
.
The "Plan" proposes that it should be based on local resources and advantages, face the world's technological frontiers and the global market, and move towards "leading" innovation; by establishing a clinical value-oriented new drug evaluation mechanism and clinical research and development guidelines, promote the optimal allocation of innovation resources and Reasonable layout of enterprise R&D pipelines to reduce excessive and repeated development of drugs with the same target; for the problem of insufficient original innovation capability, it is necessary to build a national strategic scientific and technological force, activate the innovation resources of universities, research institutes, and medical institutions, and further improve the innovation support service system
.
The "Plan" also pointed out that the innovation incentive policy should be improved to promote the application of innovative products
.
The "Plan" proposes to steadily improve the level of medical insurance financing, continue to promote the dynamic adjustment of medical insurance catalogues and access negotiations, improve the price formation mechanism for new drugs, vigorously develop commercial health insurance, improve the access procurement policies of medical institutions, and promote the market-oriented application of innovative products.
.
The industry said that these policy measures are of great significance for encouraging innovation, cultivating blockbuster products of innovative drugs, and improving the contribution rate of innovative drugs to industry growth
.
At present, my country is at an important historical point in moving from a large pharmaceutical manufacturing country to a pharmaceutical innovation powerhouse, but the originality of pharmaceutical research and development is still insufficient.
Facing the future, my country needs to continuously promote the innovation of the pharmaceutical industry, such as improving the research and development of original and high clinical value products and the strategy of going overseas.
, to promote the transformation of domestic pharmaceutical companies from local leaders to global innovation drivers
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
China needs to continuously improve its original innovation capabilities, speed up innovation and upgrade, improve innovation incentive policies, and promote the application of innovative products
.
The "14th Five-Year Plan" period will be a critical period for China's pharmaceutical innovation-driven transformation
.
According to the industry, with the investment of a large number of innovative resources in the past ten years, a large number of new drugs under research in China have entered the harvest period
.
It is predicted that during the "14th Five-Year Plan" period, there may be more than 200 domestic new drug applications (NDA)/biological product license applications (BLA), and more than 100 new drugs may be approved, shifting from the R&D investment stage to the commercialization stage
.
How to innovate in the pharmaceutical industry? Insiders pointed out that basic research is the source of medical innovation
.
In recent years, the total R&D investment in China's pharmaceutical field has increased significantly, and the level of basic pharmaceutical research has made great progress, "but there is still a big gap with the world's advanced level, mainly due to the unreasonable distribution of R&D investment, the need to improve high-quality cutting-edge research, and the transformation of patents into production.
Problems such as troubles, lack of professional institutions and talents
.
" the person said
.
It suggested that in terms of pharmaceutical innovation, China needs to make efforts from three aspects: optimizing the talent training and evaluation system, exploring the upgrading of the main innovation model, and optimizing the way of public investment in basic research, and continue to promote basic research in pharmaceutical innovation
.
Establish a talent evaluation system that pursues original innovation and encourages the transformation of basic research results, strengthens the cultivation of compound research and industrial talents with backgrounds in science, medicine, pharmacy, information technology, etc.
, to build a talent exchange channel between academia, medicine, and industry, and promote a reasonable two-way circulation of talents to fully connect basic research, clinical needs and commercial applications
.
In addition, some people also suggested to increase funding for basic research on drug innovation and optimize the environment for drug research and development
.
For example, the establishment of scientific research funds suitable for the joint application of pharmaceutical companies and scientific research institutions such as universities, the introduction of more tax incentives and other policies to expand socialized non-profit institutions to increase funding for drug research and development,
etc.
It is understood that for pharmaceutical innovation, the "14th Five-Year Plan for the Development of Pharmaceutical Industry" (referred to as the "Plan") proposes the direction and focus of pharmaceutical innovation in the next step
.
Among them, the "Plan" pointed out that the original innovation ability should be improved and the innovation and upgrading should be accelerated
.
The "Plan" proposes that it should be based on local resources and advantages, face the world's technological frontiers and the global market, and move towards "leading" innovation; by establishing a clinical value-oriented new drug evaluation mechanism and clinical research and development guidelines, promote the optimal allocation of innovation resources and Reasonable layout of enterprise R&D pipelines to reduce excessive and repeated development of drugs with the same target; for the problem of insufficient original innovation capability, it is necessary to build a national strategic scientific and technological force, activate the innovation resources of universities, research institutes, and medical institutions, and further improve the innovation support service system
.
The "Plan" also pointed out that the innovation incentive policy should be improved to promote the application of innovative products
.
The "Plan" proposes to steadily improve the level of medical insurance financing, continue to promote the dynamic adjustment of medical insurance catalogues and access negotiations, improve the price formation mechanism for new drugs, vigorously develop commercial health insurance, improve the access procurement policies of medical institutions, and promote the market-oriented application of innovative products.
.
The industry said that these policy measures are of great significance for encouraging innovation, cultivating blockbuster products of innovative drugs, and improving the contribution rate of innovative drugs to industry growth
.
At present, my country is at an important historical point in moving from a large pharmaceutical manufacturing country to a pharmaceutical innovation powerhouse, but the originality of pharmaceutical research and development is still insufficient.
Facing the future, my country needs to continuously promote the innovation of the pharmaceutical industry, such as improving the research and development of original and high clinical value products and the strategy of going overseas.
, to promote the transformation of domestic pharmaceutical companies from local leaders to global innovation drivers
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
